First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
Por:
van de Donk, NWCJ, Vega, G, Perrot, A, Anguille, S, Oriol, A, Minnema, M, Kaiser, MF, Lee, HC, Garfall, A, Matous, JV, Sanchez, LJ, Borogovac, A, Karlin, L, Usmani, SZ, Weidman, J, Lee, SM, Mateos, MV, Rodríguez-Otero, P, Touzeau, C and Popat, R
Publicada:
1 jun 2025
Resumen:
Filiaciones:
Minnema, M:
Univ Med Ctr Utrecht, Utrecht, Netherlands
Kaiser, MF:
Royal Marsden NHS Trust, London, England
Lee, HC:
Univ Texas MD Anderson Canc Ctr, Houston, TX USA
Garfall, A:
Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA USA
Matous, JV:
Colorado Blood Canc Inst, Denver, CO USA
Borogovac, A:
City Hope Natl Med Ctr, Duarte, CA USA
Karlin, L:
Ctr Hosp Lyon Sud, Serv Hematol Clin, Pierre Benite, France
Usmani, SZ:
Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
Weidman, J:
Johnson & Johnson, Spring House, PA USA
Mateos, MV:
Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain
Rodríguez-Otero, P:
Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
Touzeau, C:
Ctr Hosp Univ Nantes, Nantes, France
Popat, R:
Univ Coll London Hosp, NHS Fdn Trust, Clin Res Facil, Natl Inst Hlth Res, London, England
Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Hematol, Amsterdam, Netherlands
Hosp Fdn Jimenez Diaz, Div Hematol, START Madrid FJD, Madrid, Spain
Univ Toulouse III Paul Sabatier, Inst Univ Canc Toulouse Oncopole, CHU Toulouse, Serv Hematol, Toulouse, France
Univ Antwerp, Antwerp Univ Hosp, Div Hematol, Antwerp, Belgium
Univ Antwerp, Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med, Antwerp, Belgium
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
Icahn Sch Med Mt Sinai, New York, NY USA
|